Fortress Biotech’s Majority-Controlled Subsidiary, Journey Medical Corporation, Receives FDA Approval for Emrosi™ for Rosacea Treatment
Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosiâ„¢ ...
BioSpace2d
FDA Action Alert: Journey, Merus, PTC and Autolus
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...
FiercePharma1d
Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care
Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...
Journey Medical announces presentation of DFD-29 data
Journey Medical (DERM) presented data assessing the dermal and systemic pharmacokinetics of oral DFD-29 versus oral Doxycycline 40 mg capsules ...
Zacks.com on MSN1d
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
US FDA approves Journey Medical's drug for long-term skin condition
Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral ...